Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.59 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17346235 | 0.89 | SIGMAR1 (0.46) | SIGMAR1TMEM97 | |
| SCHEMBL17346116 | 0.87 | SIGMAR1 (0.50) | SIGMAR1TMEM97 | |
| SCHEMBL17346240 | 0.87 | KDM4E (0.46) | SIGMAR1TMEM97 | |
| SCHEMBL17346233 | 0.87 | SIGMAR1 (0.45) | SIGMAR1TMEM97 | |
| SCHEMBL17345880 | 0.85 | CARM1 (0.47) | SIGMAR1TMEM97ACKR3CARM1PRMT6 | |
| SCHEMBL17346164 | 0.85 | REN (0.44) | SIGMAR1TMEM97 | |
| SCHEMBL17346065 | 0.83 | APP (0.48) | ACKR3APPACHE | |
| SCHEMBL17345915 | 0.83 | SIGMAR1 (0.43) | SIGMAR1TMEM97 | |
| SCHEMBL17346251 | 0.83 | KCNH2 (0.43) | SIGMAR1TMEM97 | |
| SCHEMBL17346049 | 0.82 | ACKR3 (0.47) | SIGMAR1TMEM97ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550139-B2 | Polydentate ligands and their complexes for molecular catalysis | TRIAD NATIONAL SECURITY, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| US-20170088571-A1 | POLYDENTATE LIGANDS AND THEIR COMPLEXES FOR MOLECULAR CATALYSIS | TRIAD NATIONAL SECURITY, LLC | 2017-03-30 | — | — | US | disclosed |
| US-20170088571-A1 | POLYDENTATE LIGANDS AND THEIR COMPLEXES FOR MOLECULAR CATALYSIS | TRIAD NATIONAL SECURITY, LLC | 2017-03-30 | — | — | US | disclosed |
| WO-2015191505-A1 | POLYDENTATE LIGANDS AND THEIR COMPLEXES FOR MOLECULAR CATALYSIS | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088571-A1 | POLYDENTATE LIGANDS AND THEIR COMPLEXES FOR MOLECULAR CATALYSIS | NANS, NCL, NCLN | SIGMAR1 412/4885TMEM97 2166/4885ACKR3 1678/4885 |
| US-10550139-B2 | Polydentate ligands and their complexes for molecular catalysis | NANS, NCL, NCLN | SIGMAR1 412/4885TMEM97 2166/4885ACKR3 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.